BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy
Schizophrenia Drug Approval Expected In September
Executive Summary
Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.